home > news > detailed info

FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies

Fujifilm Diosynth Biotechnologies

College Station, Texas, October 24 2022 — FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today a strategic collaboration with RoosterBio, Inc. , a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio’s industry leading process development technology for both MSC and extracellular vesicle (EV) / exosome programs into its manufacturing capabilities and offerings.

This collaboration offers biopharma customers an end-to-end solution for development and production of MSC and exosome therapeutics, allowing for seamless transition of programs from RoosterBio’s process and analytical development services into FUJIFILM Diosynth Biotechnologies’ advanced therapies GMP capabilities. Manufacturing services and expertise provided by FUJIFILM Diosynth Biotechnologies will include cell expansion and collection of MSCs, downstream processing for exosome purification, and drug product manufacturing. Terms of the agreement were not disclosed.

“This collaboration will enable us to become a fully integrated cell therapy CDMO partner to our biopharma customers,” said Gerry Farrell, chief operating officer, FUJIFILM Diosynth Biotechnologies, Texas and California. “MSC products are known to have great potential in areas such as regenerative medicine and immune system modulation. In addition, exosomes are attractive as drug delivery vehicles as well as therapeutics. The partnership is aligned with our core purpose of advancing tomorrow’s medicines by enabling the advancement of our customer’s pipelines in this space.”

“FUJIFILM Diosynth Biotechnologies is a global leader in the manufacturing of advanced therapies and is creating the industry’s largest network of biologics CDMO facilities,” said Tim Kelly, chief executive officer, RoosterBio. “Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities. Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to partner with FUJIFILM Diosynth Biotechnologies to translate our MSC and exosome technologies into advanced therapy products for patients around the world.”
phone +44 (0)1642 363511
email Fujifilm Diosynth Biotechnologies Belasis Avenue Billingham TS23 1LH
Print this page
Send to a friend
News and Press Releases

New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukaemia

 BEERSE, BELGIUM, 10 December 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93),1 which showed fixed-duration treatment with IMBRUVICA® (ibrutinib) + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukaemia (CLL) compared to patients treated with chlorambucil plus obinutuzumab (Clb+O).1 These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, U.S.1
More info >>

White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement